title: Targeted therapies: Using β-blockers to inhibit breast cancer progression.
abstract: Three recent population studies have translated laboratory investigations into a clinical setting and concur in presenting evidence that suggest a dramatic new role for β-blockers in reducing metastases, tumor recurrence and specific mortality in breast cancer. Should we be skeptical about these controversial findings?
authors.affiliation: Department of Cellular Pathology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, UK. des.powe@nottingham.ac.uk
authors.forename: Desmond G
authors.initials: DG
authors.lastname: Powe
authors.forename: Frank
authors.initials: F
authors.lastname: Entschladen
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D005260:Female; D006801:Humans
chemical_list: D000319:Adrenergic beta-Antagonists